BioCentury
ARTICLE | Company News

CRL for Sandoz's biosimilar rituximab

May 3, 2018 6:15 PM UTC

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it received late Wednesday a complete response letter from FDA for a BLA for GP2013, the company's biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY).

Sandoz said it is evaluating the letter...

BCIQ Target Profiles

CD20